Similarly, pharmacological stimulation of SIRT1 by sirtuin-activating compounds (STACs), such as resveratrol, SRT1720, and SRT2104, has been reported to protect against HFD-induced obesity and insulin resistance in animals and humans [15,16,17,18]. Here, SIRT1 is linked to Insulin resistance.